大鼠MMP-13重组腺病毒载体的构建

目的　构建大鼠MMP1 3重组腺病毒载体。方法　将MMP1 3cDNA目的片段插入腺病毒柯氏质粒中 ,再将此质粒与腺病毒DNA末端蛋白复合物共转染 2 93细胞 ,通过同源重组构建MMP1 3 重组腺病毒载体。结果　MMP1 3 重组腺病毒载体经PCR鉴定正确 ,包装纯化后 ,检测病毒滴度为 4× 1 0 9PFU/ml。结论　成功地构建了RatMMP1 3 重组腺病毒载体 ,为下一步行MMP 1 3转基因治疗低顺应性膀胱的研究提供了条件     

反义人端粒酶RNA组分基因对胃癌细胞端粒酶活性的影响

目的 克隆人胃癌细胞端粒酶RNA组分（hTR）基因片段并构建其正义和反义真核表达载体,研究反义端粒酶RNA对人胃癌细胞株MKN-45端粒酶活性的影响。方法 采用RT-PCH方法从人胃癌细胞株MKN-45中扩增出人hTR部分cDNA序列,将该片段分别正向和反向插入PEF6/V5-His-TOPO载体后构建人端粒酶RNA组分（hTR）基因正、反义真核表达载体,随后采用脂质体转染法将该正、反义载体转染入人胃癌细胞株MKN-45,用TRAP法观察后者端粒酶活性的改变。结果 所克隆的基因片段其碱基序列与文献报导完全一致,且插入载体的方向完全正确。与正常对照、转染正义载体、空载体者比较,转染反义载体者端粒酶活性显著下降。结论 本实验已成功克隆了人端粒酶RNA组分（hTR）基因的部分序列并成功构建hTR正反义真核表达载体,而且反义端粒酶RNA能有效降低人胃癌细胞株MKN-45端粒酶活性。     

p21WAF1与p27KIP1真核双表达载体的构建鉴定及在胃癌细胞中的表达

目的 构建p21WAF1与p27KIP1真核双表达载体,体外转染胃癌7901细胞,观察其在胃癌细胞中的表达及相关特性.方法 提取人全血总RNA,利用逆转录-聚合酶链反应(RT-PCR)扩增p21WAF1和p27WAF1基因并将其分别克隆到真核双表达载体pIRES中构建重组质粒pIPES-p27KIP1-p21WAF1,经酶切和测序鉴定重组质粒.脂质体介导重组质粒plRES-p27KIP1.p21WAF1"转染胃癌7901细胞,收集并提取转染后12、24、48、72 h和5 d各细胞的总RNA,逆转录成cDNA,荧光定量聚合酶链反应(FQ-PCR)检测各细胞中p21WAF1和p27KIP1在RNA水平的表达.带有绿色荧光蛋白的pIRES-EGFP作为对照.结果 RT-PCR扩增分别获得约500和600 bp大小的产物,重组质粒pIRES-p27KIP1.p21WAF1经酶切和测序鉴定证实为p21WAF1和p27KIP1基因.转染胃癌7901细胞48 h时转染率为68%.与空质粒对照组比较,重组质粒转染胃癌7901细胞12、24、48、72 h和5 d后FQ-PCR证实p27KIP1的Ct值(cycle threshold,Ct)分别减少8.2、10、10、7.4和6.7,p21WAF1的Ct值分别减少7.4、8.2、8.2、6.3和5.70其中24 h和48 h的Ct值减少最大.结论 真核双表达载体pIRES-p27KIP1.p21WAF1构建成功并能在胃癌7901细胞内高效表达.     

METase在不同原核表达系统中的表达和活性比较

目的：构建L-蛋氨酸γ-裂解酶（Metase）基因的两种高效原核表达载体，建立最佳高效原核表达体系。方法：在Metase基因已经克隆的基础上，通过分子克隆技术构建两种重组表达质粒pBV220-Metase和pGEX-4T-1-Metase,重组质粒转化感受态大肠杆菌Dh5α,诱导表达，测定Metase活性，统计分析比较。结果：成功构建出两种高效重组表达质粒pBV220-Metase和pGEX-4T-1-Metase,经诱导后都能测出Metase活性。结果：重组表达质粒pBV220-Metase具有比pGEX-4T-1-Metase更强的活性，可作为Metase的高效表达体系。     

多模式临床支持系统的研究进展

目的探讨多模式临床支持系统的研究进展。方法通过了解国际多模式临床支持系统发展和运作情况,并与传统的临床支持系统进行对比,探讨多模式临床支持系统的国际研究进展情况。结果在多模式临床支持系统概念、目的及特点认识的基础上,了解了多模式临床支持系统的国际进展情况。结论临床支持系统模式的发展和演变,为多学科协作诊治模式提供了新的临床辅助,加强了循证医学的临床实践和相应的提升体系,但临床支持系统项目在目前我国医院的应用还需要进一步探讨和研究。     

凋亡素基因序列重组及其真核表达载体的构建

目的:提高凋亡素基因在肿瘤细胞中的表达效率,增强其诱导肿瘤细胞凋亡的生物学活性.方法:通过两次PCR,以pcDNA-VP3质粒为模板,扩增出带Kozak序列(真核核糖体结合位点)的凋亡素基因VP3.将其克隆到真核表达载体pRevTRE的多克隆位点,构建成凋亡素的真核表达载体pRevTRE-VP3,将该质粒分别以限制性内切酶BamHI和XhohI进行酶切鉴定,将初步鉴定显示可能克隆有目的基因的质粒进行测序鉴定.结果:测序结果表明,本研究合成的凋亡素基因与Noteborn报告的凋亡素基因序列一致,同源性为l 00%.在其起始密码子前添加了Ko zak序列的凋亡素基因已成功克隆到真核表达载体pRevTRE.结论:采用两次PCR法可提高表达效率的真核核糖体结合位点添加到凋亡素基因序列起始密码子前端,并构建成凋亡素真核表达载体.     

雷帕霉素靶蛋白反义RNA真核表达载体的构建及其在血管平滑肌细胞中的表达

目的构建雷帕霉素靶蛋白（mTOR）的反义RNA真核表达载体，观察其对血管平滑肌细胞（VSMC）功能的影响。方法提取人VSMC总RNA，逆转录．聚合酶链反应（RT-PCR）扩增mTOR基因cDNA序列，经pGEM-T载体克隆后双酶切，将cDNA序列反向插入绿色荧光蛋白表达载体pEGP-C1，转染VSMC，Westernblot法检测反义表达载体对mTOR蛋白表达的影响，流式细胞仪检测细胞周期的变化。结果经RT-PCR获得664bp产物，T载体克隆后，酶切确定该片段为mTOR基因cDNA，进而构建反义RNA真核表达载体pEGFP-C1-mTOR，测序证明序列正确后转染VSMC，证实其能够显著抑制mTOR蛋白产物表达，转染72h的mTOR蛋白产物表达抑制率达82％，S期细胞由15％降低为7％，凋亡细胞增至9％。VSMC增殖过程在Gx／Go期→S期受阻。结论成功构建mTOR基因的反义RNA真核表达载体。     

The relational underpinnings of quality internal auditing in medical clinics in Israel

Internal auditing is a key mechanism in enhancing organizational reliability. However, research on the ways quality internal auditing is enabled through learning, deterrence, motivation and process improvement is scant. In particular, the relational underpinnings of internal auditing have been understudied. This study attempts to address this need by examining how organizational trust, perceived organizational support and psychological safety enable internal auditing. Data collected from employees in medical clinics of one of the largest healthcare organizations in Israel at two points in time six months apart. Our results show that organizational trust and perceived organizational support are positively related to psychological safety (measured at time 1), which, in turn, is associated with internal auditing (measured at time 2).     

NIKKISO DBB-27型血液透析机液路系统工作原理及故障报警分析

分析了NIKKISO DBB-27型血液透析机液路系统的系统结构及各组成部分的工作原理,并对相关故障报警的诊断和排除进行了详细论述,为及时、准确地诊断和排除血液透析机的故障提供了理论基础。     

Analysis of the circumstances at the end of life in children with cancer: Symptoms, suffering and acceptance

BACKGROUND: In an effort to improve the quality of life of children with cancer, this study analyzes the signs and symptoms at the end of life in such children. It is hoped that these data will contribute to the development of appropriate programs to address the challenges faced by these children. PROCEDURE: Between 1994 and 2000, 28 children died after treatment for cancer at Hamamatsu University Hospital, Japan. The circumstances, signs and symptoms at the end of life of these children were analyzed through their medical records. RESULTS: Of the 28 children, the underlying diseases were leukemia/lymphoma (LL group; n=11), brain tumors (BT group; n=7), and other solid tumors (OST group; n=10). Records showed poor appetite (100%), dyspnea (82.1%), pain (75.0%), fatigue (71.4%), nausea/vomiting (57.1%), constipation (46.4%) and diarrhea (21.4%) among these children. Anxiety was reported in 53.6% of the entire group of 28 children; however, no child in the BT group manifested anxiety. However, disturbance of consciousness was reported in all children in the BT group, which was significantly greater than in the other groups. Awareness, fear or acceptance of the imminence of his/her own death as indicated by verbal expression was reported in nine children (32.1%). CONCLUSIONS: Using the data obtained in the present study, we describe situations faced in the terminal care of children. It is important to address the problems revealed by this analysis in order to achieve improvements in both the physical and psychological care of children with terminal cancer.